SHARE
COPY LINK

VACCINE

BioNTech: How the German firm is leading the Covid-19 vaccine race

The small German biotech firm BioNTech, started by a husband and wife team with Turkish roots, had never brought a vaccine to market before.

BioNTech: How the German firm is leading the Covid-19 vaccine race
The entrance to BioNTech's headquarters in Mainz. Photo: DPA

But its experimental technology has now become the first authorised for use
in the Western world to help end the coronavirus pandemic.

Along with its US partner Pfizer, BioNTech on Wednesday said its Covid-19 vaccine has been granted approval by Britain, with a rollout planned for as early as next week.

Cancer pioneer

Mainz-based BioNTech was co-founded in 2008 by Ugur Sahin and his wife Ozlem Tureci, both scientists and the children of Turkish immigrants to Germany, as well as Austrian cancer expert Christoph Huber.

In normal times, BioNTech and its roughly 1,500 employees are focused on developing specialised immunotherapies for cancer patients based on “messenger RNA” (mRNA) molecules that trigger the building of proteins in cells, to stimulate the immune system.

It's this same technology, which has the benefit that it can be developed more quickly than traditional vaccines, that lies at the heart of its Covid-19 shot.

The vaccine will introduce synthetic mRNA into the human body to trick the immune system into producing the viral proteins needed to provoke a safe but robust offensive against the coronavirus.

Early in the starting blocks

Sahin, 54, jumped into action in January shortly after reading about the emergence of a new and deadly coronavirus in the Chinese city of Wuhan.

By the time much of the planet was in lockdown in March, BioNTech had developed 20 vaccine candidates based on mRNA technology, he told Der Spiegel weekly.

Those were eventually whittled down to a handful of the most promising options, with vaccine BNT162b2 now the frontrunner.

Teaming up with Pfizer

Having struck a deal with US pharma giant Pfizer to work together to develop mRNA-based flu vaccines in 2018, teaming up on a potential coronavirus vaccine was an obvious next move for BioNTech.

The two companies announced in March that they aimed to jointly develop a Covid-19 jab, “pairing Pfizer's development, regulatory and commercial capabilities with BioNTech's mRNA vaccine technology and expertise”, they said at the time.

Photo: DPA

While global headlines tend to lead with Pfizer's involvement, Sahin insisted to Spiegel: “It is our technology.”

The cooperation is a good fit because it allows BioNTech “to develop and distribute a possible vaccine in the shortest time possible”, he added.

Global rollout

The BNT162b2 vaccine will require two jabs to be effective.

BioNTech and Pfizer have said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion in 2021.

READ ALSO: December vaccine rollout possible in December: BioNTech CEO

In a clear sign that they were gearing up for mass production, BioNTech in September bought a manufacturing site in Marburg in western Germany from Swiss pharma group Novartis, along with its 300 employees, allowing it to produce millions of additional doses each year.

BioNTech already has two other production sites in Germany, while at least four Pfizer sites in the United States and Europe will join in the unprecedented effort to roll out a vaccine at record speed.

Sahin had told AFP in an interview in November that if all the players involved — governments, pharma companies and vaccine logistics firms — “do a really good job”, then “we can succeed in vaccinating 60 to 70 percent of the population by the autumn of 2021.”

“And when we've accomplished that then we could have a normal winter. Without another shutdown.”

Besides Britain, the European Union and a slew of countries including the US and Japan have already placed orders for millions of doses of the BioNTech-Pfizer vaccine as nations eagerly await the regulatory nods.

BioNTech has also struck a deal with Shanghai-based Fosun Pharmaceutical Group, which will have the exclusive rights to bring the vaccine to China.

By Sophie Makris

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

Munich sees sharp rise in Covid cases after Oktoberfest

Since the start of Germany’s Oktoberfest, the incidence of Covid infections in Munich has risen sharply. Though a connection with the festival can’t yet be proven, it seems likely.

Munich sees sharp rise in Covid cases after Oktoberfest

Two weeks after the start of Oktoberfest, the Covid numbers in Munich have more than tripled.

On Sunday, the Robert Koch Institute (RKI) reported an incidence of 768.7 for the city of Munich, though updated figures for the end of the festival are not expected until later in the week. Usually, on weekends and public holidays, there is a delay in reports.

In the entire state of Bavaria, the incidence value on Sunday was 692.5.

According to Munich’s public health officer, Beatrix Zurek, bed occupancy in Munich hospitals has also increased. Two weeks ago, 200 beds in Munich were occupied by Covid patients, whereas there are now around 350.

Though a relationship between the sharp rise in infections with Oktoberfest, which ended on Monday, can’t be proven at the moment, it seems very likely, according to experts. A significant increase in Covid incidences has also been shown at other public festivals – about one and a half weeks after the start. 

READ ALSO: Germany’s famed Oktoberfest opens after two-year pandemic hiatus

After a two-year break due to the pandemic, around 5.7 million visitors came to this year’s Wiesn according to the festival management – around 600,000 fewer than at the last Oktoberfest before the pandemic in 2019, when there were 6.3 million.

Federal Health Minister Karl Lauterbach (SPD) took to Twitter to comment on the rise in incidence in Munich during the Oktoberfest. “This would not have been necessary if self-tests had been taken before admission,” he said.

“Compared to the price of a measure of beer, €2-3 (for tests) wouldn’t have mattered,” he said.

Even before the start of the Wiesn, he had spoken out in favour of people taking voluntary self-tests. Lauterbach stressed that now is the time for special measures against Covid.

“The development shows what will happen if the states wait too long with the mask obligation in indoor areas,” he added.

READ ALSO: KEY POINTS: Germany’s new Covid-19 rules from October

In neighbouring counties, where many Oktoberfest visitors came from, the number of Covid cases has also risen noticeably.  Beatrix Zurek said that it is unclear, however, how much of a role Oktoberfest played in these figures, as people are currently much more active socially overall, with concerts and other events also taking place throughout the state.

Christoph Spinner, an infections specialist at Munich’s Klinikum, has urged people not to be alarmed by the rising numbers.

“We had expected rising incidences here. We knew that there could be a doubling, tripling, even quadrupling,” he said.

He said that this is no cause for concern, as many people have been vaccinated or have also recovered from previous Covid infections, so any new infections are therefore usually mild.

The virologist advises people over 60 or with pre-existing conditions to get a second booster vaccination, but otherwise said people shouldn’t be alarmed by the rising incidences.

SHOW COMMENTS